NASDAQ
45.83USD
+0.69 (+1.53%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
0.87
52W range
14.27-50.18
Day range
44.99–46.11
Open
45.09
Prev close
45.14
Volume
334.6K
Avg volume
464.7K
Dividend
0.00
IPO
2018-11-14
https://www.globenewswire.com/news-release/2026/08/05/3339150/0/en/Eton-Pharmaceuticals-Expands-Infantile-Hemangioma-Franchise-with-Acquisition-of-U-S-Rights-to-Late-Stage-Product-Candidate-ASN-001.html · 8/5/2026+0.80
https://www.globenewswire.com/news-release/2026/07/29/3335064/0/en/Eton-Pharmaceuticals-Announces-Submission-of-Prior-Approval-Supplement-to-Expand-Indication-of-KHINDIVI-hydrocortisone-Oral-Solution.html · 7/29/2026+0.80
https://www.gurufocus.com/news/8892233/eton-pharmaceuticals-inc-eton-shares-fall-43-what-gf-score-of-70-tells-investors · 5/30/2026-0.40
https://www.globenewswire.com/news-release/2026/05/01/3285807/0/en/eton-pharmaceuticals-relaunches-hemangeol-propranolol-oral-solution-with-eton-cares-and-exclusive-specialty-pharmacy-distribution.html · 5/1/2026
https://www.globenewswire.com/news-release/2026/04/27/3281436/0/en/eton-pharmaceuticals-announces-initiation-of-clinical-study-for-product-candidate-et-700.html · 4/27/2026+0.60
https://www.zacks.com/stock/news/2887386/does-eton-pharmaceuticals-eton-have-the-potential-to-rally-49-25-as-wall-street-analysts-expect?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2887386 · 3/20/2026+0.80
https://www.zacks.com/stock/news/2886939/eton-pharmaceuticals-inc-eton-q4-earnings-lag-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2886939 · 3/19/2026-0.40
https://www.globenewswire.com/news-release/2026/02/20/3241822/0/en/Eton-Pharmaceuticals-to-Participate-at-Leerink-Partners-Global-Healthcare-Conference-on-Wednesday-March-11th.html · 2/20/2026+0.80
https://seekingalpha.com/article/4839967-eton-pharmaceuticals-inc-eton-q3-2025-earnings-call-transcript · 11/7/2025+0.00
https://www.globenewswire.com/news-release/2025/11/06/3183094/0/en/Eton-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html · 11/6/2025+1.00
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
